Showing 161 - 180 results of 52,260 for search '(( 50 ((ng decrease) OR (((we decrease) OR (a decrease)))) ) OR ( a non decrease ))', query time: 1.03s Refine Results
  1. 161

    The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

    Published 2019
    “…(D) The level of REST dramatically reduced in differentiated SH-SY5Y cells treated with GA (1 μM) or PU-H71 (50 nM) at 24 h. (E) The REST level decreased by GA more than 50% and (F) PU-H71 more than 80%, respectively. …”
  2. 162
  3. 163
  4. 164
  5. 165

    Receptor specific silencing decreases NGF induced apoptosis. by Alessandra Micera (294762)

    Published 2013
    “…A 37.5%-decrease (*) and a 50%-decrease (**) of apoptotic signal were detected respectively in p75<sup>NTR</sup>-siRNA and p75<sup>NTR</sup>/trkA<sup>NGFR</sup>-siRNA (p<.05).…”
  6. 166
  7. 167
  8. 168

    Lower insular perfusion in the DAT group compared with the non-DAT group. by Masashi Takeuchi (1930312)

    Published 2022
    “…In the region of interest-based analysis, decrease extent ratios were higher in the DAT group (N = 12) than in the non-DAT group (N = 38) (D). …”
  9. 169
  10. 170
  11. 171
  12. 172

    Data_Sheet_5_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  13. 173
  14. 174

    Data_Sheet_4_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  15. 175

    Data_Sheet_3_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  16. 176

    Data_Sheet_1_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  17. 177

    Data_Sheet_1_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  18. 178

    Data_Sheet_2_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  19. 179

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 180